血液系统恶性肿瘤的免疫治疗：过去、现在与未来。
Immunotherapy in hematologic malignancies: past, present, and future.
作者信息
Im Annie, Pavletic Steven Z
机构信息
University of Pittsburgh Cancer Institute, 5150 Centre Ave, Suite 554, Pittsburgh, PA, 15213, USA.
National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
出版信息
J Hematol Oncol. 2017 Apr 24;10(1):94. doi: 10.1186/s13045-017-0453-8.
Abstract
The field of immunotherapy in cancer treatments has been accelerating over recent years and has entered the forefront as a leading area of ongoing research and promising therapies that have changed the treatment landscape for a variety of solid malignancies. Prior to its designation as the Science Breakthrough of the Year in 2013, cancer immunotherapy was active in the treatment of hematologic malignancies. This review provides a broad overview of the past, present, and potential future of immunotherapy in hematologic malignancies.
摘要
近年来，癌症治疗中的免疫疗法领域发展迅速，已成为前沿领域，作为一个正在进行研究且有前景的治疗领域，改变了多种实体恶性肿瘤的治疗格局。在2013年被指定为年度科学突破之前，癌症免疫疗法就已活跃于血液系统恶性肿瘤的治疗中。本文综述了免疫疗法在血液系统恶性肿瘤治疗中的过去、现状及潜在的未来发展情况。
相似文献
1
Immunotherapy in hematologic malignancies: past, present, and future.血液系统恶性肿瘤的免疫治疗：过去、现在与未来。
J Hematol Oncol. 2017 Apr 24;10(1):94. doi: 10.1186/s13045-017-0453-8.
2
Checkpoint inhibitors in AML: are we there yet?AML 中的检查点抑制剂：我们成功了吗？
Br J Haematol. 2020 Jan;188(1):159-167. doi: 10.1111/bjh.16358. Epub 2019 Dec 6.
3
Immune checkpoint inhibitors.免疫检查点抑制剂。
J Cell Biol. 2019 Mar 4;218(3):740-741. doi: 10.1083/jcb.201810035. Epub 2019 Feb 13.
4
Immunotherapy in genitourinary malignancies.泌尿生殖系统恶性肿瘤的免疫治疗
J Hematol Oncol. 2017 Apr 24;10(1):95. doi: 10.1186/s13045-017-0457-4.
5
The next generation of immunotherapy: keeping lung cancer in check.下一代免疫疗法：控制肺癌
J Hematol Oncol. 2017 Apr 24;10(1):87. doi: 10.1186/s13045-017-0456-5.
6
[Not Available].[无可用内容]
Bull Cancer. 2018 Dec;105 Suppl 1:S1-S2. doi: 10.1016/S0007-4551(18)30384-9.
7
Efficacy and safety of immune checkpoint blockade for brain metastases.免疫检查点阻断治疗脑转移瘤的疗效与安全性。
CNS Oncol. 2019 Jun;8(2):CNS33. doi: 10.2217/cns-2018-0018. Epub 2019 Mar 11.
8
Atypical autoimmune adverse effects with checkpoint blockade therapies.检查点阻断疗法的非典型自身免疫不良反应。
Ann Oncol. 2017 Feb 1;28(2):206-207. doi: 10.1093/annonc/mdw658.
9
Emerging role of immunotherapy in urothelial carcinoma-Advanced disease.免疫疗法在尿路上皮癌晚期疾病中的新作用。
Urol Oncol. 2016 Dec;34(12):538-547. doi: 10.1016/j.urolonc.2016.10.017.
10
Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.免疫疗法在上尿路上皮癌中的新兴作用——免疫生物学/生物标志物
Urol Oncol. 2016 Dec;34(12):556-565. doi: 10.1016/j.urolonc.2016.10.006. Epub 2016 Nov 9.
引用本文的文献
1
Cord blood-derived iNK T cells as a platform for allogeneic CAR T cell therapy.脐带血来源的iNK T细胞作为异基因嵌合抗原受体T细胞疗法的一个平台。
Front Immunol. 2025 May 30;16:1621260. doi: 10.3389/fimmu.2025.1621260. eCollection 2025.
2
Tug of war: Understanding the dynamic interplay of tumor biomechanical environment on dendritic cell function.拔河：理解肿瘤生物力学环境对树突状细胞功能的动态相互作用。
Mechanobiol Med. 2024 Apr 27;2(3):100068. doi: 10.1016/j.mbm.2024.100068. eCollection 2024 Sep.
3
Recent advances of chimeric antigen receptor T-cell therapy for acute myeloid leukemia.嵌合抗原受体T细胞疗法治疗急性髓系白血病的最新进展
Front Immunol. 2025 May 2;16:1572407. doi: 10.3389/fimmu.2025.1572407. eCollection 2025.
4
Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines.血液癌症的新一代免疫治疗方法：探索嵌合抗原受体T细胞（CAR-T）和癌症疫苗的疗效。
Exp Hematol Oncol. 2025 May 17;14(1):75. doi: 10.1186/s40164-025-00662-3.
5
Unveiling the potential of CLL-1: a promising target for AML therapy.揭示CLL-1的潜力：急性髓系白血病治疗的一个有前景的靶点。
Biomark Res. 2025 Feb 12;13(1):28. doi: 10.1186/s40364-025-00738-6.
6
Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies.急性髓系白血病治疗的变革：基于免疫疗法的系统综述
Discov Oncol. 2025 Jan 26;16(1):89. doi: 10.1007/s12672-025-01797-9.
7
New insight in immunotherapy and combine therapy in colorectal cancer.结直肠癌免疫治疗与联合治疗的新见解。
Front Cell Dev Biol. 2025 Jan 7;12:1453630. doi: 10.3389/fcell.2024.1453630. eCollection 2024.
8
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges.癌症纳米免疫疗法的现状与未来：机遇、障碍与挑战
Mol Cancer. 2025 Jan 18;24(1):26. doi: 10.1186/s12943-024-02214-5.
9
The Effect of Atorvastatin on Oncogenic miRNAs in Hematological Malignancies: A Central Study.阿托伐他汀对血液系统恶性肿瘤中致癌性微小RNA的影响：一项核心研究。
Biomolecules. 2024 Dec 7;14(12):1559. doi: 10.3390/biom14121559.
10
Immune Characteristics and Immunotherapy of HIV-Associated Lymphoma.人类免疫缺陷病毒相关淋巴瘤的免疫特征与免疫治疗
Curr Issues Mol Biol. 2024 Sep 10;46(9):9984-9997. doi: 10.3390/cimb46090596.
本文引用的文献
1
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.一项vadastuximab talirine 单药治疗 CD33 阳性急性髓系白血病患者的 1 期临床试验。
Blood. 2018 Jan 25;131(4):387-396. doi: 10.1182/blood-2017-06-789800. Epub 2017 Dec 1.
2
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.
3
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038.
4
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.纳武利尤单抗用于自体干细胞移植和维布妥昔单抗均治疗失败后的经典型霍奇金淋巴瘤：一项多中心、多队列、单臂2期试验。
Lancet Oncol. 2016 Sep;17(9):1283-94. doi: 10.1016/S1470-2045(16)30167-X. Epub 2016 Jul 20.
5
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.表达抗B细胞成熟抗原嵌合抗原受体的T细胞可使多发性骨髓瘤缓解。
Blood. 2016 Sep 29;128(13):1688-700. doi: 10.1182/blood-2016-04-711903. Epub 2016 Jul 13.
6
Ipilimumab for Patients with Relapse after Allogeneic Transplantation.伊匹单抗用于异基因移植后复发的患者。
N Engl J Med. 2016 Jul 14;375(2):143-53. doi: 10.1056/NEJMoa1601202.
7
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.在接受维布妥昔单抗治疗失败的经典型霍奇金淋巴瘤患者中使用帕博利珠单抗进行程序性死亡-1阻断治疗。
J Clin Oncol. 2016 Nov 1;34(31):3733-3739. doi: 10.1200/JCO.2016.67.3467.
8
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.奥滨尤妥珠单抗联合苯达莫司汀对比苯达莫司汀单药治疗利妥昔单抗难治性惰性非霍奇金淋巴瘤（GADOLIN）：一项随机、对照、开放标签、多中心、3 期临床试验。
Lancet Oncol. 2016 Aug;17(8):1081-1093. doi: 10.1016/S1470-2045(16)30097-3. Epub 2016 Jun 23.
9
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.奥英妥珠单抗对比标准疗法治疗急性淋巴细胞白血病
N Engl J Med. 2016 Aug 25;375(8):740-53. doi: 10.1056/NEJMoa1509277. Epub 2016 Jun 12.
10
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.达雷妥尤单抗单药治疗在多次预处理的复发或难治性多发性骨髓瘤患者中的临床疗效。
Blood. 2016 Jul 7;128(1):37-44. doi: 10.1182/blood-2016-03-705210. Epub 2016 May 23.
Zotero 插件